News Release

 

Back
 

AmerisourceBergen Stockholders Elect Board Members and Approve Employee Stock Purchase Plan

02/27/02
VALLEY FORGE, Pa., Feb 27, 2002 (BUSINESS WIRE) -- AmerisourceBergen Corporation (NYSE:ABC) stockholders today elected four members of the Board of Directors and approved the Company's Employee Stock Purchase Plan at the first Annual Meeting of Stockholders of AmerisourceBergen Corporation, which was held in Philadelphia, PA.

The four members elected to the Board today were: Rodney H. Brady, President and Chief Executive Officer of Deseret Management Corporation; Charles H. Cotros, Chairman and Chief Executive Officer of Sysco Corporation; Jane E. Henney, M.D., Senior Scholar in Residence at the Association of Academic Health Centers; and R. David Yost, President and Chief Executive Officer of AmerisourceBergen Corporation.

The terms of each of those elected today will expire at the Annual Meeting in 2005. The Company's Board of Directors currently consists of ten directors.

AmerisourceBergen stockholders also approved the Company's 2002 Employee Stock Purchase Plan as outlined in the Proxy Statement dated January 22, 2002.

    About AmerisourceBergen
AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternative care facilities, independent community pharmacies, and regional drugstore chains.

The Company is also a leader in the institutional pharmacy marketplace. With approximately $39 billion in annualized operating revenues, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

    Forward-Looking Statements
This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between AmeriSource Health Corporation and Bergen Brunswig Corporation.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its most recent 10-Q, its Annual Report on Form 10-K for fiscal 2001, and AmeriSource's and Bergen's joint proxy statement-prospectus dated August 1, 2001.

AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

CONTACT:          AmerisourceBergen Corporation, Valley Forge
                  Michael N. Kilpatric, 610/727-7118
                  mkilpatric@amerisource.com

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More